



RECEIVED

SEP 24 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

Applicant(s): Elisabettni et al.
Appl. No.: 10/044,234
Filed: January 11, 2002
Title: BICARBONATE-BASED SOLUTIONS FOR DIALYSIS THERAPIES
Art Unit: 1616
Examiner: Unknown
Docket No.: DI-5782

Assistant Commissioner for Patents
Washington, DC 20231

#7
AKD
9-27-02

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 37 C.F.R. 1.97, and 37 C.F.R. 1.98, Applicants request that a citation and examination of the references cited below, and on the attached PTO-1449 form, copies of which are enclosed, be made during the course of examination of the above-identified application for United States patent.

FOREIGN PATENT DOCUMENTS

| <u>Document No.</u> | <u>Date</u> | <u>Country</u> |
|---------------------|-------------|----------------|
| JP 56164113 - | 12-17-81 | Japan |
| EP 0 083 360 - | 07-13-83 | Europe |
| EP 0 165 933 B1 - | 01-02-86 | Europe |
| WO 86/03407 - | 06-19-86 | PCT |
| EP 0 209 607 - | 01-28-87 | Europe |
| WO 87/03809 - | 07-02-87 | PCT |
| EP 0 249 667 B1 - | 12-23-87 | Europe |
| EP 0 277 868 A2 - | 08-10-88 | Europe |
| EP 0 278 100 A2 - | 08-17-88 | Europe |
| EP 0 399 549 A1 - | 11-28-90 | Europe |
| 0 399 918 A2 - | 11-28-90 | Europe |
| JP 2304026 - | 12-17-90 | Japan |
| 0 417 478 A1 - | 03-20-91 | Europe |
| 0 437 274 A1 - | 07-17-91 | Europe |
| EP 0 439 061 B1 - | 07-31-91 | Europe |
| JP 3195561 - | 08-27-91 | Japan |

| <u>Document No.</u> | <u>Date</u> | <u>Country</u> |
|---------------------|-------------|----------------|
| WO 91/18610 ~ | 12-12-91 | PCT |
| 0 481 257 A1 ~ | 04-22-92 | Europe |
| JP 5105633 ~ | 04-27-93 | Japan |
| JP 6105905 ~ | 04-19-94 | Japan |
| EP 0 613 688 A1 ~ | 09-07-94 | Europe |
| EP 0 647 145 B1 ~ | 04-12-95 | Europe |
| WO 95/19778 ~ | 07-27-95 | PCT |
| JP 7252137 ~ | 10-03-95 | Japan |
| WO 96/01118 ~ | 01-18-96 | PCT |
| JP 8131542 ~ | 05-28-93 | Japan |
| JP 8164199 ~ | 06-25-96 | Japan |
| WO 97/05851 ~ | 02-20-97 | PCT |
| JP 9087182 ~ | 03-31-97 | Japan |
| JP 9110703 ~ | 04-28-97 | Japan |
| EP 0 776 649 A2 ~ | 06-04-97 | Europe |
| JP 9301875 ~ | 11-25-97 | Japan |
| FR 2 753 099 ~ | 03-13-98 | France |
| WO 98/10733 ~ | 03-19-98 | PCT |
| JP 10201821 ~ | 08-04-98 | Japan |
| JP 11004872 ~ | 01-12-99 | Japan |
| WO 99/01144 ~ | 01-14-99 | PCT |
| JP 11-9659 ~ | 01-19-99 | Japan |
| JP 11-19178 ~ | 01-26-99 | Japan |
| WO 99/09953 ~ | 03-04-99 | PCT |
| DE 19748290 ~ | 05-06-99 | Germany |
| EP 0 935 967 A2 ~ | 08-18-99 | Europe |
| EP 1166787 ~ | 01-02-02 | Europe |

OTHER DOCUMENTS

- Manahan et al., *Peritoneal Dialysis using bicarbonate-containing solution sterilized by ultrafiltration*, The International Journal of Artificial Organs, Vol. 14 no. 8, 1999, pp. 463-465.
- Murphy et al., *Use of an Artificial Kidney*, Vol. 40, 1952, pp. 436-444.
- Tjiang, Boen San, *A Clinical Study of Factors Governing its Effectiveness*, Peritoneal Dialysis, p. 76, Van Gorcum & Co., Assen, The Netherlands (1959).
- Feriani et al., *Short-Term Clinical Study with Bicarbonate-Containing Peritoneal Dialysis Solution*, Peritoneal Dialysis International, Vol. 13, pp. 296-301 (1993).
- The Merck Index, 12th Ed., Merck Research Laboratories, Whitehouse Station, NJ, 9 1472 (1996).
- Odel et al., *Peritoneal Lavage as an Effective Means of Extraenal Excretion. A Clinical Appraisal*, American Journal of Medicine, Vol. 9, 63-88 (1950).
- Schambye et al., *The Cytotoxicity of Continuous Ambulatory Peritoneal Dialysis Solutions with Different Bicarbonate/Lactate Ratios*, Peritoneal Dialysis International Vol. 13, Suppl. 2, Oct. 1-4, pp. S116-S118 (1994).
- Schambye et al., *Bicarbonate-versus Lactate-Based CAPD fluids: A Biocompatibility Study in Rabbits*, Peritoneal Dialysis International, Vol. 12, pp. 281-286 (1992).
- Simonsen et al., *Less Infusion Pain and Elevated Level of Cancer Antigen 125 by the Use of a New and More Biocompatible PD Fluid*, Advances in Peritoneal Dialysis, Vol. 12, pp. 156-160 (1996).
- Ing., et al., *Bicarbonate-Buffered Peritoneal Dialysis*, The International Journal of Artificial Organ, Vol. 8, No. 3, p. 121-124 (1985).
- Zhou et al., *Effects of an Acidic, Lactate-Based Peritoneal Dialysis Solution and its Euhydric, Bicarbonate-Based Counterpart on Neutrophilic Interacellular pH*, Int. J. Artif. Organs, Vol. 16, No. 12, pp. 816-819 (1993).
- American Society for Artificial Internal Organs, 1994 Abstracts, pp 110.
- Faller et al., *Loss of Ultrafiltration in Continuous Ambulatory Peritoneal Dialysis: A Role for Acetate*, Peritoneal Dialysis Bulletin, January-March 1984, pp 10-13.
- Ing et al., *Lactate-Containing Peritoneal Dialysis Solutions*, International J. of Artificial Organs, Vol. 16, No. 10, 1993, pp 688-693.
- Ing et al., *Lactate-Containing Versus Bicarbonate-Containing Peritoneal Dialysis Solutions*, Peritoneal Dialysis International, Vol. 12, pp 276-277.

Ing et al., *Preparation of Bicarbonate-Containing Dialysate for Peritoneal Dialysis*, International J. of Artificial Organs, Vol. 6, No. 4, 1983, pp 217-218.

Manahan et al., *Effects of Bicarbonate-Containing Versus Lactate-Containing Peritoneal Dialysis Solutions on Superoxide Production by Human Neutrophils*, Artificial Organs, Vol. 13, No. 6, 1989, pp. 495-497.


Richardson et al., *Bicarbonate, L-Lactate, and D-Lactate Balance in Intermittent Peritoneal Dialysis*, Peritoneal Dialysis Bulletin, Vol. 6, No. 4, 1986, pp. 178-185.

Yatzidis, Hippocrates, *A New Stable Bicarbonate Dialysis Solution for Peritoneal Dialysis: Preliminary Report*, Peritoneal Dialysis International, Vol. 11, pp. 224-227.


An early and favorable consideration of this matter is respectfully requested.

Respectfully submitted,

BELL, BOYD & LLOYD LLC

A handwritten signature in black ink, appearing to read 'BY' followed by a stylized, cursive signature.

Robert M. Barrett
Reg. No.30,142
P.O. Box 1135
Chicago, Illinois 60690-1135
Phone: (312) 807-4204

| | | | |
|---|---------------------------------|-----------------------|------------------------|
|  TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c)) | | Docket No. DI-5782 | |
| In Patent Application Of: Elisabettini et al. | | | |
| Serial No. 10/044,234 | Filing Date January 11, 2002 | Examiner Unknown | Group Art Unit 1616 |
| Title: BICARBONATE-BASED SOLUTIONS FOR DIALYSIS THERAPIES | | | |
| <p style="text-align: center;">Address to: Assistant Commissioner for Patents Washington, D.C. 20231</p> <p style="text-align: center;">37 CFR 1.97(b)</p> <p>1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.</p> <p style="text-align: center;">37 CFR 1.97(c)</p> <p>2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:</p> <p style="padding-left: 40px;"><input type="checkbox"/> the statement specified in 37 CFR 1.97(e);</p> <p style="text-align: center;">OR</p> <p style="padding-left: 40px;"><input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).</p> | | | |

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
DI-5782

Re Application: Elisabettni et al.

Serial No.
10/044,234

Filing Date
January 11, 2002

Examiner
Unknown

Group Art Unit
1616

BICARBONATE-BASED SOLUTIONS FOR DIALYSIS THERAPIES

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. _____ as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on 09-18-2002 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Signature of Person Mailing Correspondence

Robert J. Buccieri

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

Dated: September 18, 2002

Signature

Robert M. Barrett

Reg. No. 30,142

BELL, BOYD & LLOYD LLC

P.O. Box 1135

Chicago, IL 60690-1135

Ph ne: 312/807-4204

CC:

SEP 23 2002

TRANSMITTAL LETTER
(General - Patent Pending)

Docket No.
DI-5782

In Patent Application Of: Elizabettni et al.

Serial No.
10/044,234

Filing Date
January 11, 2002

Examiner
Unknown

Group Art Unit

Title: **BICARBONATE-BASED SOLUTIONS FOR DIALYSIS THERAPIES**

RECEIVED
SEP 24 2002
TECH CENTER 1600/2900

TO THE ASSISTANT COMMISSIONER FOR PATENTS:

Transmitted herewith is:

Transmittal of Information Disclosure Statement (duplicate); Supplemental Information Disclosure Statement (4 pgs.); Supplemental Information Disclosure Citation PTO Form 1449 (4 pgs.); 62 references; return receipt postcard.

in the above identified application.

- ☒ No additional fee is required.
- ☐ A check in the amount of _____ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. **02-1818** as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.


Signature

Dated: September 18, 2002

Robert M. Barrett
Reg. No. 30,142

BELL, BOYD & LLOYD LLC
P.O. Box 1135
Chicago, IL 60690-1135
Phone: 312-807-4204

I certify that this document and fee is being deposited on 09-18-2002 with the U.S. Postal Service as first class mail under 39 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.


Signature of Person Mailing Correspondence

Robert J. Buccieri

Typed or Printed Name of Person Mailing Correspondence

CC: